A population pharmacokinetic study to accelerate early phase clinical development for a novel drug, teriflunomide sodium, to treat systemic lupus erythematosus-Reference-Cited by-同舟云学术

A population pharmacokinetic study to accelerate early phase clinical development for a novel drug, teriflunomide sodium, to treat systemic lupus erythematosus

Published:2019-08 Issue: Volume:136 Page:104942
ISSN:0928-0987
Container-title:European Journal of Pharmaceutical Sciences
language:en
Short-container-title:European Journal of Pharmaceutical Sciences

Author:

Yao Xueting^ORCID,Wu Yiwen,Jiang Ji,Chen Xia,Liu Dongyang,Hu Pei

Funder

Ministry of Science and Technology of the People's Republic of China

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference32 articles.

1. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models;Bergstrand;AAPS J.,2011

2. Investigation of the influence of CYP1A2 and CYP2C19 genetic polymorphism on 2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide (A77 1726) pharmacokinetics in leflunomide-treated patients with rheumatoid arthritis;Bohanec Grabar;Drug Metab. Dispos.,2009

3. Population pharmacokinetics and association between A77 1726 plasma concentrations and disease activity measures following administration of leflunomide to people with rheumatoid arthritis;Chan;Br. J. Clin. Pharmacol.,2005

4. Teriflunomide Sodium Tablet Investigator's Brochure;Cinkate Pharmaceutical Intermediates (Shanghai) Co., Ltd,2014

5. Stability and performance of a population pharmacokinetic model;Ette;J. Clin. Pharmacol.,1997

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety of teriflunomide in Chinese adult patients with relapsing multiple sclerosis: A phase IV, 24-week multicenter study;Chinese Medical Journal;2024-02-05

2. Development of a population pharmacokinetic model and optimal dosing regimen of leflunomide in Korean population;European Journal of Pharmaceutical Sciences;2023-05

3. Genetic Polymorphisms and the Clinical Response to Systemic Lupus Erythematosus Treatment Towards Personalized Medicine;Frontiers in Pharmacology;2022-03-18

4. ABCB1, ABCG2, ABCC1, ABCC2, and ABCC3 drug transporter polymorphisms and their impact on drug bioavailability: what is our current understanding?;Expert Opinion on Drug Metabolism & Toxicology;2021-02-02

5. Population Pharmacokinetics Study of Contezolid (MRX-I), a Novel Oxazolidinone Antibacterial Agent, in Chinese Patients;Clinical Therapeutics;2020-05